health-and-pharmaceuticals2.98 min read
"Altimmune's Pemvidutide Minimizes Muscle Loss in Obesity Drug Trial"
1 year ago•Source: CNBC
Health And Pharmaceuticals News
The latest health and pharmaceuticals stories, summarized by AI
Featured Health And Pharmaceuticals Stories
View original source
1.585 min•1 year ago
"Viking Therapeutics' Oral Weight-Loss Drug Shows Promise in Phase 1 Study"
Viking Therapeutics' experimental weight-loss tablet, VK2735, showed promising results in a small early-stage trial, with the highest 40-milligram dose leading to a 3.3% weight loss in participants. The company's shares rose 15% following the news. Viking plans to continue testing higher doses and expects to initiate a mid-stage study in obese patients later this year. The drug's oral version could offer a more convenient option for patients, especially those who have achieved significant weight loss with the injectable version.
More Top Stories
2
3
More Health And Pharmaceuticals Stories
"Novo Nordisk's Breakthrough Weight-Loss Pill Sends Stock Soaring, Surpasses Tesla's Market Cap"
Novo Nordisk's weight loss drugs Ozempic and Wegovy have been incredibly popular, with the company now teasing a new pill that could be twice as powerful as Wegovy. An early-stage trial found that an oral version of the drug amycretin led to users losing 13% of their body weight after 12 weeks of treatment, causing Novo Nordisk stock to surge to a record high. If successful, this new medication could lead to even faster weight loss and potentially make Novo Nordisk even more valuable than Tesla.
"Viking Therapeutics' Breakthrough Weight Loss Drug Sparks Investor Frenzy"
Viking Therapeutics has emerged as a strong contender in the weight loss drug market, with its experimental obesity treatment showing promising results in a midstage trial, leading to a 120% surge in its shares. Analysts believe the company's injectable drug may be "best-in-class," outperforming competitors like Eli Lilly and Novo Nordisk. However, Viking still faces challenges in manufacturing and regulatory approval, and its drug may not reach the market until 2029. Despite this, the company's impressive data has made it an attractive target for potential partnerships or acquisitions by larger pharmaceutical companies looking to enter the weight loss drug market.
"Viking Therapeutics' Weight-Loss Drug Trial Yields Impressive Results, Stock Doubles"
Viking Therapeutics' stock doubled after reporting positive results from a Phase 2 trial of its weight-loss drug VK2735, showing statistically significant reductions in body weight at all doses compared to placebo, with patients losing up to 14.7% of their body weight after 13 weeks. The treatment was well-tolerated, and the company plans to discuss next steps with the FDA. The news positions Viking as a potential competitor in the weight-loss drug market, and the company is also developing a treatment for NASH.
"Survodutide: A Promising Competitor in the Weight-Loss Drug Market"
Zealand Pharma's stock surged over 34% after positive results in a clinical trial for a liver disease drug that also shows promise for weight loss, potentially challenging market leaders Novo Nordisk and Eli Lilly. Novo Nordisk's sales are projected to increase by up to 26% in 2024 due to the demand for weight loss drugs like Wegovy and Ozempic, with the potential for the company to become one of the first trillion-dollar pharmaceutical companies. Competition in the weight loss drug market is intensifying, with several companies, including Regeneron, Amgen, and Viking Pharmaceuticals, racing to introduce new drugs to compete with the current market leaders.
"Weight-Loss Drugs: Impact on US GDP and Heart Health Discussed by Valley Doctors"
Goldman Sachs predicts that the widespread use of weight-loss drugs in the US could increase the country's GDP by 1% due to improved workplace efficiency from lower obesity-related health issues. The market for these drugs is expected to reach $100bn annually, with potential for significant economic impact. However, the use of these drugs is controversial, and their effects on broader health and societal issues are being closely watched.
"FTC Investigates Middlemen's Role in Generic Drug Shortages"
The Biden administration is investigating the role of drug wholesalers and group purchasing organizations in causing shortages of generic drugs, which make up the majority of prescriptions in the U.S. The Federal Trade Commission and the Department of Health and Human Services are seeking public input on whether these middlemen have used their market power to drive down prices to the point where manufacturers can't profit, leading to production stoppages and discouraging competition. The public will have 60 days to submit comments, and the investigation comes amid ongoing efforts to address high drug costs.
Gilead Sciences Acquires CymaBay Therapeutics for $4.3 Billion
Gilead Sciences has announced the acquisition of CymaBay Therapeutics for $4.3 billion, adding seladelpar, an investigational treatment for primary biliary cholangitis (PBC), to its liver portfolio. Seladelpar, with FDA priority review and anticipated U.S. approval in the third quarter of 2024, has shown promising results in Phase 3 trials, offering a potential treatment for PBC, a rare liver disease. The acquisition aligns with Gilead's commitment to addressing unmet needs in liver diseases and is expected to enhance its revenue growth upon FDA approval of seladelpar.
Novo Nordisk Boosts Supply of Weight-Loss Drug Wegovy Amid Growing Demand
Novo Nordisk has boosted the supply of its weight loss drug Wegovy, allowing more patients in the U.S. to start taking the medication. The increased supply of the lowest dose aims to address previous restrictions that prevented new patients from beginning treatment. The company's efforts to maintain supply for existing users led to supply shortages for new patients, prompting some to be prescribed off-label alternatives. Novo Nordisk also noted improvements in insurance coverage for Wegovy, potentially benefiting around 50 million people in the U.S. with obesity.
Ozempic's Rise: Marketing Blitz, Lobbying, and Real-life Challenges
Novo Nordisk's blockbuster weight loss drug, Ozempic, has become one of the most hyped treatments in American history, thanks to a $1 billion marketing campaign and millions spent lobbying physicians to promote the drug. However, the company now faces numerous lawsuits from patients claiming crippling side effects, with allegations of aggressive marketing tactics to promote their drugs as the only way to achieve sustainable weight loss. Celebrities have also contributed to the drug's popularity, with sales surging over 300 percent and bringing massive profits for Novo Nordisk.
"Rising Competition in the Booming Weight Loss Drug Market"
Drugmakers are racing to enter the weight loss drug market, which is expected to be worth tens of billions in the next decade. Companies like Boehringer Ingelheim, Terns Pharmaceuticals, Viking Therapeutics, and Structure Therapeutics are developing weight loss drugs targeting gut hormones like GLP-1 and glucagon. With demand for obesity medications projected to grow, smaller players are aiming to compete with dominant companies like Novo Nordisk and Eli Lilly. Large pharmaceutical companies like Sanofi and Bayer are also considering entering the market through potential partnerships or next-generation weight loss drugs.